Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Ophthalmology

Treating CRVO: Injections and Beyond

At a Glance

The standard treatment for central retinal vein occlusion (CRVO) is anti-VEGF eye injections, which reduce retinal swelling and help prevent permanent vision loss. The injection procedure is very quick and uses numbing drops to ensure patient comfort, usually causing only brief pressure.

Managing Central Retinal Vein Occlusion (CRVO) is a marathon, not a sprint. The primary goal of treatment is to reduce the swelling in your eye and prevent more serious complications that can lead to permanent vision loss [1][2]. While the idea of eye treatments can be intimidating, modern therapies are highly effective and designed with patient comfort in mind.

First-Line Therapy: Anti-VEGF Injections

The standard “gold-standard” treatment for the swelling (macular edema) caused by CRVO is a class of medications called anti-VEGF agents [2][3]. These drugs include aflibercept, ranibizumab, and bevacizumab [4].

  • How they work: Think of these drugs as “chemical plugs” for leaky pipes. In CRVO, the body produces a protein called VEGF (Vascular Endothelial Growth Factor) that makes blood vessels leaky and weak [2]. Anti-VEGF injections neutralize this protein, helping to dry up the fluid and reduce swelling [4][3].
  • The Timeline: Once treatment starts, many patients begin to notice an improvement in their vision within one to two weeks, though it can take a few injection cycles to achieve maximum clarity [1]. Most patients begin with a series of monthly injections. Your doctor may eventually switch to a “treat-and-extend” plan, where the time between injections is gradually increased as long as your eye remains stable [5][6].

Other Treatment Options

If anti-VEGF injections are not enough, or if your condition is particularly severe, your specialist might recommend:

Steroid Implants

Corticosteroids, such as the dexamethasone implant, are sometimes used to reduce inflammation and swelling [2][3]. These are tiny, dissolvable implants placed inside the eye that release medication over several months [7]. While effective, they carry a higher risk of increasing eye pressure or causing cataracts, so they are often used as a second-line option [8][7].

Panretinal Photocoagulation (PRP) Laser

In cases of ischemic CRVO, the eye may try to grow abnormal new blood vessels (neovascularization) [9]. If these vessels appear on the iris or in the “drainage angle” of the eye, a laser treatment called PRP is used [9][10]. The laser creates tiny burns on the peripheral retina to stop the drive for new vessel growth, protecting you from severe complications like neovascular glaucoma [9][11].

What to Expect During an Injection

The thought of an eye injection is often much worse than the procedure itself. Here is the typical experience designed to keep you safe and comfortable:

  1. Preparation and Numbing: The specialist will use several rounds of numbing drops or a small anesthetic gel to ensure you don’t feel the needle [12].
  2. Cleaning: The eye and surrounding area are cleaned with an antiseptic (usually iodine) to prevent infection [13].
  3. The Speculum: A small, comfortable instrument called a speculum is placed over the eyelids. This holds the eye open, so you do not have to worry about blinking during the procedure.
  4. The Injection: The specialist will ask you to look in a specific direction. The injection itself takes only a second or two. Most patients describe it as a quick “pressure” sensation rather than sharp pain [14][15].
  5. Aftercare and Logistics: You may see a “bubble” or “floater” for a day, and your eye might feel slightly scratchy. This is normal. You can use over-the-counter artificial tears to soothe the scratchiness, but you should avoid rubbing the eye, swimming, or wearing eye makeup for a few days to prevent infection [16][17]. Severe pain or sudden vision loss should be reported immediately [16][17].

Logistical Note: Because your eye will be dilated and your vision may be blurry or sensitive to light after the procedure, it is highly recommended that you bring a driver to transport you home after your appointment.

Finding the Right Specialist

Because CRVO requires specialized imaging and procedures, you should be under the care of a retina specialist—an ophthalmologist who has completed an extra 1–2 years of fellowship training specifically in diseases of the retina [18][19]. When vetting a specialist, look for one who:

  • Uses advanced imaging like OCT at every visit to track your progress [20].
  • Communicates clearly about your specific subtype (ischemic vs. non-ischemic) [21].

Common questions in this guide

How do anti-VEGF injections help treat CRVO?
Anti-VEGF medications work by blocking a specific protein that causes blood vessels in your eye to become weak and leaky. By neutralizing this protein, the injections help dry up the leaked fluid and reduce swelling in the retina, which can improve your vision.
Does getting an eye injection for CRVO hurt?
The procedure is designed to be as comfortable as possible and is not usually painful. Your retina specialist will use several rounds of numbing drops or an anesthetic gel beforehand, so most patients only feel a quick sensation of pressure for a second or two.
What happens if anti-VEGF injections do not work for my CRVO?
If standard injections are not effectively reducing the swelling, your doctor might recommend a corticosteroid implant. This is a tiny, dissolvable implant placed inside the eye that slowly releases anti-inflammatory medication over the course of several months.
When is PRP laser treatment used for CRVO?
A laser treatment called panretinal photocoagulation (PRP) is used if you develop ischemic CRVO, where the eye attempts to grow abnormal new blood vessels. The laser creates tiny burns that stop this dangerous vessel growth and protect the eye from severe complications like neovascular glaucoma.
What should I expect immediately after my eye injection?
It is normal to see a small bubble or floater in your vision for a day, and your eye might feel slightly scratchy. Because your eye will be dilated for the procedure, your vision will be temporarily blurry and sensitive to light, so you must bring someone to drive you home.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which anti-VEGF medication do you recommend for me, and why?
  2. 2.Based on my imaging, is anti-VEGF therapy the right first step, or should we consider a steroid implant?
  3. 3.What is your protocol for numbing and cleaning the eye before an injection?
  4. 4.Is my CRVO ischemic enough that I might need PRP laser in the future?
  5. 5.What signs should I look for that indicate I need an injection sooner than scheduled?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.

    Hykin P, Prevost AT, Vasconcelos JC, et al.

    JAMA ophthalmology 2019; (137(11)):1256-1264 doi:10.1001/jamaophthalmol.2019.3305.

    PMID: 31465100
  2. 2

    Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion.

    Lee KH, Kang EC, Koh HJ

    Yonsei medical journal 2017; (58(3)):676-678 doi:10.3349/ymj.2017.58.3.676.

    PMID: 28332380
  3. 3

    Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.

    Sangroongruangsri S, Ratanapakorn T, Wu O, et al.

    Expert review of clinical pharmacology 2018; (11(9)):903-916 doi:10.1080/17512433.2018.1507735.

    PMID: 30071180
  4. 4

    Comparison of vascular endothelial growth factor inhibitors on macular oedema secondary central retinal vein occlusion.

    Teo KYC, Mohla A, Cheung CMG

    Eye (London, England) 2020; (34(2)):221-222 doi:10.1038/s41433-019-0707-5.

    PMID: 31772385
  5. 5

    Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.

    Korobelnik JF, Larsen M, Eter N, et al.

    American journal of ophthalmology 2021; (227()):106-115 doi:10.1016/j.ajo.2021.01.027.

    PMID: 33556381
  6. 6

    INJECTION FREQUENCY OF AFLIBERCEPT VERSUS RANIBIZUMAB IN A TREAT-AND-EXTEND REGIMEN FOR CENTRAL RETINAL VEIN OCCLUSION: A Randomized Clinical Trial.

    Casselholm de Salles M, Amrén U, Kvanta A, Epstein DL

    Retina (Philadelphia, Pa.) 2019; (39(7)):1370-1376 doi:10.1097/IAE.0000000000002171.

    PMID: 29624543
  7. 7

    Location of a Dexamethasone Implant at the Macula after Intravitreal Injection in a Silicone Oil-Filled Eye.

    Esenulku CM, Gunay M

    Case reports in ophthalmological medicine 2016; (2016()):5107652 doi:10.1155/2016/5107652.

    PMID: 27999699
  8. 8

    Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.

    Wittström E

    The open ophthalmology journal 2017; (11()):89-102 doi:10.2174/1874364101711010089.

    PMID: 28603574
  9. 9

    Efficacy of panretinal laser in ischemic central retinal vein occlusion: A systematic review.

    Li C, Wang R, Liu G, et al.

    Experimental and therapeutic medicine 2019; (17(1)):901-910 doi:10.3892/etm.2018.7034.

    PMID: 30651879
  10. 10

    Efficacy and Safety of Laser Therapy on Ischemic Central Retinal Vein Occlusion: A Systematic Review and Analysis of Clinical Studies.

    Alotaibi GF, Seraj H, AlMulihi QA, et al.

    Cureus 2024; (16(6)):e62292 doi:10.7759/cureus.62292.

    PMID: 39006605
  11. 11

    Photocoagulation for retinal vein occlusion.

    Hayreh SS

    Progress in retinal and eye research 2021; (85()):100964 doi:10.1016/j.preteyeres.2021.100964.

    PMID: 33713810
  12. 12

    Pain perception during intravitreal injections is related to the timing of instilling anesthetic eyedrops.

    Voichanski S, Totah H, Hanhart J

    International ophthalmology 2024; (44(1)):383 doi:10.1007/s10792-024-03315-2.

    PMID: 39302600
  13. 13

    Rates of endophthalmitis before and after transition from povidone-iodine to aqueous chlorhexidine asepsis for intravitreal injection.

    Stephenson KA, Merkur A, Kirker A, et al.

    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2024; (59(6)):424-429 doi:10.1016/j.jcjo.2024.01.012.

    PMID: 38387861
  14. 14

    REDUCTION OF POSTINTRAVITREAL INJECTION PAIN USING ICE: An Open-Label Interventional Randomized Controlled Trial.

    Yahalomi T, Hecht I, Lagstein O, et al.

    Retina (Philadelphia, Pa.) 2020; (40(7)):1434-1438 doi:10.1097/IAE.0000000000002608.

    PMID: 31305506
  15. 15

    Impact of Anxiety Levels and Sleep Patterns on Perceived Pain During Intravitreal Bevacizumab Injections.

    Wieder MS, Szlechter M, Fischman N, et al.

    Ophthalmic surgery, lasers & imaging retina 2021; (52(9)):498-504 doi:10.3928/23258160-20210819-02.

    PMID: 34505802
  16. 16

    Intravitreal Injection Therapy: Current Techniques and Supplemental Services.

    Lam LA, Mehta S, Lad EM, et al.

    Journal of vitreoretinal diseases 2021; (5(5)):438-447 doi:10.1177/24741264211028441.

    PMID: 37008713
  17. 17

    Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.

    Al-Rashaed S, Alsulaiman SM, Alrushood AA, et al.

    Middle East African journal of ophthalmology 2016; (23(1)):60-3 doi:10.4103/0974-9233.171756.

    PMID: 26957840
  18. 18

    Central Retinal Vein Occlusion: A Review of Current Evidence-based Treatment Options.

    Patel A, Nguyen C, Lu S

    Middle East African journal of ophthalmology 2016; (23(1)):44-8 doi:10.4103/0974-9233.173132.

    PMID: 26957838
  19. 19

    Comparative efficacy and safety of antivascular endothelial growth factors for central retinal vein occlusion: A protocol for systematic review and network meta-analysis.

    Liu Z, Wang S, Ma A, Zhao B

    Medicine 2021; (100(52)):e28283 doi:10.1097/MD.0000000000028283.

    PMID: 34967360
  20. 20

    Hyperreflectivity of Inner Retinal Layers as a Quantitative Parameter of Ischemic Damage in Acute Retinal Vein Occlusion (RVO): An Optical Coherence Tomography Study.

    Furashova O, Matthè E

    Clinical ophthalmology (Auckland, N.Z.) 2020; (14()):2453-2462 doi:10.2147/OPTH.S260000.

    PMID: 32921978
  21. 21

    Characteristics of Central Retinal Vein Occlusion in African Americans.

    Kiew SY, Thomas GN, Thomas AS, Fekrat S

    Journal of vitreoretinal diseases 2020; (4(3)):186-191 doi:10.1177/2474126419882829.

    PMID: 37007449

This page provides educational information about CRVO treatments, including eye injections and laser therapy. Always consult with your retina specialist to determine the safest and most effective treatment plan for your specific eye condition.

Get notified when new evidence is published on Central retinal vein occlusion.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.